This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Healthcare Europe

Bringing clarity from confusion

EliA CTD Screen, the most clinically relevant and reliable CTD Screen, brings clarity from confusion

Connective tissue diseases
can be hard to diagnose

The diverse and overlapping symptoms of connective tissue diseases (CTDs), particularly early in the course of the disease, can make diagnosis challenging.1-7

Automated diagnostic tests, in conjunction with a thorough history, can help diagnose CTDs earlier.

Reliable testing in primary care can help to: 8-10

  • Determine if referral to a specialist is appropriate
  • Ensure effective and timely treatment
  • Prevent organ damage

1 test, 1 result, 17 antibodies

EliACTD Screen measures 17 autoantibodies, in one test with one result, to support you in the diagnosis of connective tissue diseases.11-14

If positive, the Phadia Laboratory System that runs EliA CTD Screen can automatically run the EliA Single parameter (ENA) tests.

EliA CTD Screen Systemic
myopathies (IMM)*
tissue disease
U1RNP (RNP 70, A, C) ++       +++
SS-A/Ro (60 kDa, 52 kDa)   +++      
SS-B/La + +++ [Primary]
++ [Secondary]
Centromere B     +++    
Scl-70     + [CREST/LcSSc]
++ [dcSSc]
Jo-1       +  
Sm + [Caucasian]12
++ [Asian or Afro-American]
Fibrillarin +   (+) [Caucasian]
+ [Asian or Afro-American]
RNA Pol III     +    
Rib-P +        
PM-Scl     ++ [Polymyositis/ Scleroderma overlap syndrome]
+ [SSc], + [IIM]
PCNA (+)        
Mi-2 proteins       ++ [Adult dermatomyositis]
+ [Juvenile dermatomyositis]
(+) Polymyositis
Native purified DNA +++        

(+): <10%, +: ≤10%-30%, ++: 31%-60%, +++: 61%-100%; *Polymyositis & dermatomyositis; LcSSc = Limited cutaneous systemic sclerosis; dcSSc = diffuse cutaneous systemic sclerosis

EliA CTD Screen –
A diagnostic test you can rely on

EliA TD Screen, validated in over 17k patients from different populations, provides you with diagnostic test results you can rely on.15-21

EliA CTD Screen showed
similar sensitivity and
higher specificity
than IIF.”15

Our results suggest that the (EliA CTD screen) may basically represent an appropriate screening test for ANA and has a high sensitivity for SS, SSc and MCTD (each 100%).”

…The sensitivity for diagnosing
SS was slightly higher
for EliA
CTD screen than for IIF.”16

EliA CTD Screen showed similar sensitivity and higher specificity than IIF.”17

The sensitivity and specificity were better for EliA CTD than for ANA IIF.”18

… When results of autoantibodies
from all 1030 sera were analyzed as
either supportive / compatible with
CTD or not relevant, the ANA-IIF
and CTD screen assays showed
similar sensitivities to detect
antinuclear antibodies in diseases…

… In contrast, the specificity of ANA-IIF was lower than that of the CTD screen assay”…19

…The CTD screen was excellent for patients with SLE, and the combination with IIF was more effective for the diagnosis of total systemic rheumatic diseases, including MCT than CTD screen alone.”20

In nine thousand eight hundred and fifty-six consecutive patients tested for ANAs…

…the positive predictive value for (ANA associated systemic rheumatic disease) was higher for EliA than for IIF.”21

EliA CTD Screen –
A diagnostic test you can rely on

EliA    CTD Screen has comparable sensitivity and superior specificity to the current “gold” standard test (ANA IIF).22

Study included unselected prospective study population of 322 patients suspected of systemic autoimmune rheumatic disease and a control group of 98 healthy blood donors. ANA measured by IIFA using INOVA Lite Hep-2 cells, according to manufacturer’s instructions using screening serum dilution of 1:80. EliA CTD Screen performed on Phadia 250 system.

Due to the superior specificity of EliA CTD Screen,22    based on 2,000 patients being tested, and a disease prevalence of 1%, 158 fewer false positives per year.

Fewer false positive results can help reduce:

  • The risk of misdiagnosis
  • The risk of incorrect treatment
  • The number of avoidable referrals from primary care
  • The cost burden on the healthcare system
thermo scientific

The choice is yours

EliA CTD Screen offers you:

  • A diagnostic test you can rely on – A single test that includes 17 autoantibodies and provides a single result, and that has been validated in over 17k patient samples from different populations15-22
  • Potentially increased turnaround time – EliA CTD Screen is run on a fully automated Phadia™ Laboratory System, potentially increasing turnaround time
  • A test that puts the patient first – EliA CTD Screen has comparable sensitivity and superior specificity to ANA IIF,15-22 meaning fewer false positives and therefore helping provide patients with the right answer sooner

Find out more at

© 2019 Thermo Fisher Scientific Inc. All rights reserved.
All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.

1. Irvine S, Munro R, Porter D. Ann Rheum Dis 1999;58:510–13. 2. Gray M, Nuki J. Rheumatology (Oxford) 2001;40(Suppl 1):60. 23. 3. Jeyaratnam R, et al. Rheumatology (Oxford) 2001;40(Suppl 1):29. 4. Potter T, Mulherin D, Pugh M. Rheumatology (Oxford) 2002;41:953–5; author reply 5. 5. Raza K, et al. Ann Rheum Dis 2011;70:1822–5. 6. Rodriguez-Polanco E, et al. Rheumatol Int 2011;31:657–65. 7. Nanji JA, et al. J Rheumatol 2012;39:707–11. 8. Kuhn A, et al. Dtsch Arztebl Int. 2015;112(25):423-32. 9. Rasmussen A, et al. Rheumatology (Oxford). 2016;55(7):1195-201. 10. Romao VC, et al. RMD Open. 2018;4(Suppl 1):e000789. 11. Hernando M, et al. Clin Chem Lab Med 2002;40:1056-60. 12. Thermo Fisher Scientific. Internal Study. 13. Takasaki Y, et al. Japanese Journal of Medicine and Pharmaceutical Science 2011;65(4):537-545. 14. Conrad K, et al. Autoantibodies in Systemic Autoimmune diseases: A Diagnostic Reference 3rd Ed: Pabst Science Publisher: 2015. 15. Korsholm T, et al. Scand J Rheumatol 2014; 43:89. 16. Robier C, et al. Clinical Chemistry and Laboratory Medicine 2016;54(8):1365-70. 17. Alpini C, et al. EliA Journal 2010 (Special Edition 1):3. 18. Pereira LM, et al. EliA Journal 2010 (Special Edition 1):6-7. 19. Otten HG, et al. Clin Exp Rheumatol 2017. 20. Jeong S, et al. PLoS ONE 2017; 12(3). 21. Willems P, et al. Clin Chem Lab Med 2018; DOI: [epub ahead of print]. 22. van der Pol P, et al. Clinica Chimica Acta 2018;476:154-159.